Project Grant R03HL183267
Award Date 4/1/26
Completion Date 2/29/28
Dollars Obligated $115K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
- Federal Project Grant Award Summary Florida International University received a $516,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of July 31, 2027. The award supports the development of novel RhoA nitration inhibitory peptides for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research addresses a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $731,827 to J. David Gladstone Institutes in San Francisco, California, under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, through June 30, 2030. This research grant funds a comprehensive investigation into the mechanisms of oxygen toxicity and potential therapeutic interventions, with a focus on understanding how excess oxygen damages...
- Federal Grant Award Summary Florida International University received a $694,398 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 21, 2025, with completion targeted for May 31, 2029. The grant supports investigator-initiated research conducted in Miami, Florida, focused on elucidating the molecular mechanisms by which toll-like receptor 4 (TLR4)-mediated mitochondrial reactive oxygen...
- Federal Grant Award Summary The University of Arizona received a $730,070 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2029. The award funds research focused on developing selective targeting nanoparticle systems to deliver therapeutic agents to lung capillary endothelial cells in neonates with bronchopulmonary dysplasia (BPD) complicated by pulmonary...
- Federal Project Grant Award Summary Michigan Technological University is conducting a three-year research project funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This $589,998 project, awarded September 1, 2025, and concluding August 31, 2028, investigates cardiac sensory and sympathetic nerve dysregulation in hypertrophic cardiomyopathy (HCM). The research aims to elucidate how aberrant mechanical and metabolic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Michigan a $1.49 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 20, 2025, with a completion date of June 30, 2030. The award funds the development of an in situ micro-rheology technique using ultrasound-responsive nanodroplets to characterize aging thrombi (blood clots) in real-time. The research addresses a...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of South Alabama a $1,150,692 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) on May 1, 2025, to investigate a novel mechanism regulating genome-wide messenger RNA expression in hypoxic lung disease. The research focuses on exploring the "BRACR" pathway (Base Oxidation and Repair Activated Chromatin Restructuring), which operates in concert with hypoxia-inducible...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $106,391 to The Regents of the University of Colorado (University of Colorado-Denver) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 9, 2025, with a completion date of August 31, 2027. This research initiative investigates the role of developmental dysanapsis—the disproportionate growth of lung compartments—in bronchopulmonary dysplasia (BPD), the chronic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $164,916 Project Grant to the University of California, Davis, effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds the OPTIPRES (Optimal Vasopressor in Persistent Pulmonary Hypertension of the Newborn) research initiative, which investigates optimal vasopressor selection for critically ill newborns experiencing perinatal...